{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-011698","form_type":"8-K","ticker":"IRMD","cik":"0001325618","company_name":"IRADIMED CORP","filed_at":"2022-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.921602+00:00","generated_at":"2026-06-27T10:59:12.679434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q4 revenue up 39% YoY to $11.9M; guides FY22 rev $51.4-52.2M","bullets":["Q4 2021 GAAP diluted EPS $0.31 vs $0.05 YoY; non-GAAP diluted EPS $0.33 vs $0.07.","Full-year 2021 revenue $41.8M (+32% YoY); full-year GAAP EPS $0.74 vs $0.11.","Gross profit margin improved to 77.9% in Q4 vs 75.3% YoY; free cash flow $10.8M for FY.","FY2022 guidance: revenue $51.4M-$52.2M, GAAP EPS $0.82-$0.90; Q1 rev $12.1M-$12.3M.","Record bookings growth: Q4 bookings +48% YoY, FY bookings +39% YoY, signaling strong demand."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-011698","json":"https://secwatch.observer/filing/0001104659-22-011698.json","markdown":"https://secwatch.observer/filing/0001104659-22-011698.md","text":"https://secwatch.observer/filing/0001104659-22-011698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325618/000110465922011698/0001104659-22-011698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325618/000110465922011698/tm225491d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T10:59:12.679434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}